BioPharma Dive - Latest News

Mirum drug for rare genetic disease gains FDA approval

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with Travere Therapeutics.

Feb 24, 2025 - 18:35
 0
Mirum drug for rare genetic disease gains FDA approval

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with Travere Therapeutics.

Read More

Tags:

Previous Article

The Rise And Fall Of Studebaker: What Went Wrong?

Next Article

Summit partners with Pfizer to study bispecific, ADC combinations

Related Posts

Drug compounders sue FDA over declaration ending Wegovy shortage

Drug compounders sue FDA over declaration ending Wegovy...

Feb 25, 2025  0

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Solid says early data suggest ‘differentiated’ Duchenne...

Feb 18, 2025  0

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

‘It’s not for the faint of heart.’ How 3 CEOs took thei...

Feb 14, 2025  0